PE107599A1 - Derivados ureido y tioureido de 4-amino-2(5h)-furanonas y 4-amino-2(5h)-tiofenonas como agentes antitumorales - Google Patents

Derivados ureido y tioureido de 4-amino-2(5h)-furanonas y 4-amino-2(5h)-tiofenonas como agentes antitumorales

Info

Publication number
PE107599A1
PE107599A1 PE1998000812A PE00081298A PE107599A1 PE 107599 A1 PE107599 A1 PE 107599A1 PE 1998000812 A PE1998000812 A PE 1998000812A PE 00081298 A PE00081298 A PE 00081298A PE 107599 A1 PE107599 A1 PE 107599A1
Authority
PE
Peru
Prior art keywords
amino
thiophenons
furanonas
thioureid
ureid
Prior art date
Application number
PE1998000812A
Other languages
English (en)
Inventor
Ernesto Menta
Gerd Zimmermann
Nicoletta Pescalli
Marco Conti
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of PE107599A1 publication Critical patent/PE107599A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/66—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA I; A Y X SON O o S; R1 Y R2 SON H, ALQUILO C1-C6; R ES ALQUILO C1-C10, CICLOALQUILO C3-C7, ALQUILTIO C1-C4, ENTRE OTROS; CON LA CONDICION QUE CUANDO A Y X SON OXIGENO, R NO ES ALQUILO C1-C10. SON COMPUESTOS PREFERIDOS 4-[N-(4-CLOROFENIL)AMINOCARBONILAMINO]-2(5H)-FURANONA, 4-[N-(4-ETIL-3-CLOROFENIL)AMINOCARBONILAMINO]-2(5H)-FURANONA. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I ES UN AGENTE ANTITUMORAL
PE1998000812A 1997-09-05 1998-09-01 Derivados ureido y tioureido de 4-amino-2(5h)-furanonas y 4-amino-2(5h)-tiofenonas como agentes antitumorales PE107599A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97115391 1997-09-05

Publications (1)

Publication Number Publication Date
PE107599A1 true PE107599A1 (es) 1999-11-03

Family

ID=8227318

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000812A PE107599A1 (es) 1997-09-05 1998-09-01 Derivados ureido y tioureido de 4-amino-2(5h)-furanonas y 4-amino-2(5h)-tiofenonas como agentes antitumorales

Country Status (16)

Country Link
US (2) US6333346B1 (es)
EP (1) EP1009747A1 (es)
JP (1) JP2001515894A (es)
KR (1) KR20010023549A (es)
CN (1) CN1278256A (es)
AR (1) AR014908A1 (es)
AU (1) AU748490B2 (es)
BR (1) BR9812629A (es)
CA (1) CA2302284A1 (es)
CO (1) CO4970714A1 (es)
HR (1) HRP980480A2 (es)
MA (1) MA24668A1 (es)
PE (1) PE107599A1 (es)
TR (1) TR200000589T2 (es)
WO (1) WO1999012917A1 (es)
ZA (1) ZA988096B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1309593B1 (it) * 1999-03-05 2002-01-24 Novuspharma Spa Composti eterociclici ad attivita' antitumorale.
KR20010094519A (ko) * 2000-03-31 2001-11-01 서경배 2,2,4,5-사중 치환된 3(2ｈ)-퓨라논 유도체의 제조 방법
GB9928696D0 (en) 1999-12-03 2000-02-02 Swan Thomas & Co Ltd Optical devices and methods of manufacture thereof
IT1315267B1 (it) * 1999-12-23 2003-02-03 Novuspharma Spa Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale
US20060211759A1 (en) * 2001-07-26 2006-09-21 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Bis-heterocyclic compounds with antitumour and chemosensitising activity
WO2003018575A1 (en) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation 5-substituted-3(2h)-furanones useful for inhibition of farnesyl-protein transferase
CA2491802C (en) * 2002-07-09 2012-04-10 Fasgen, Inc. Novel compounds, pharmaceutical compositions containing same, and methods of use for same
KR20040018295A (ko) * 2002-08-22 2004-03-03 임철부 항암 활성을 갖는 티오우레이도 세라마이드 유도체 및 이화합물을 함유하는 약학적 조성물
KR100555655B1 (ko) * 2002-11-20 2006-03-03 임철부 항암 활성을 갖는 우레이도 또는 티오우레이도 유도체 및이 화합물을 함유하는 약학조성물
CN1301253C (zh) * 2003-07-31 2007-02-21 中国人民解放军军事医学科学院毒物药物研究所 五元硫杂环类化合物及其用于制备治疗和预防肥胖相关疾病的药物的用途
CN101161645B (zh) * 2007-11-27 2010-06-23 南京大学 尿素类衍生物及其制备方法与用途
CN101560175B (zh) * 2009-05-08 2012-10-10 南京大学 一类硫脲类衍生物及其制备方法与用途
CN106800544B (zh) * 2017-01-19 2019-09-06 华南师范大学 3-卤-4-联苯胺基-2(5h)-呋喃酮类化合物及其在制备抗肿瘤药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE27894E (en) * 1972-05-15 1974-01-22 Hydroxy-j-(j-phenylureido)crotonic acid, gamma lactone compounds
AR206143A1 (es) * 1974-04-17 1976-06-30 Du Pont Procedimiento para la preparacion de compuestos de 1 - t - alquil - 3 - (2,5 - dihidro - 5 - oxo - 3 - furil) ureas
SE7702004L (sv) * 1976-03-24 1977-09-25 Du Pont Antihypertensiva furylkarbamider
JPS63174983A (ja) * 1987-01-16 1988-07-19 Sumitomo Chem Co Ltd アミノブテノリド誘導体、その製造法およびそれを有効成分とする除草剤

Also Published As

Publication number Publication date
JP2001515894A (ja) 2001-09-25
AU748490B2 (en) 2002-06-06
MA24668A1 (fr) 1999-07-01
CO4970714A1 (es) 2000-11-07
EP1009747A1 (en) 2000-06-21
US20020058694A1 (en) 2002-05-16
BR9812629A (pt) 2000-08-22
AU9535098A (en) 1999-03-29
HRP980480A2 (en) 1999-06-30
US6333346B1 (en) 2001-12-25
CN1278256A (zh) 2000-12-27
CA2302284A1 (en) 1999-03-18
WO1999012917A1 (en) 1999-03-18
TR200000589T2 (tr) 2000-07-21
AR014908A1 (es) 2001-04-11
KR20010023549A (ko) 2001-03-26
ZA988096B (en) 2000-03-22

Similar Documents

Publication Publication Date Title
PE107599A1 (es) Derivados ureido y tioureido de 4-amino-2(5h)-furanonas y 4-amino-2(5h)-tiofenonas como agentes antitumorales
AR002740A1 (es) Compuesto derivado de la isotiazolona y formulacion farmaceutica con el mismo.
ES2126658T3 (es) Compuesto de 2-amino-1,3-propanodiol e inmunosupresor.
EA199800943A1 (ru) Производные мочевины и их применение в качестве ингибиторов инозин-5`-монофосфат- дегидрогеназы
YU1299A (sh) 1,4-disupstituisani derivati piperidina koji sadrže fluor
AR039489A1 (es) Derivados de tetrahidropiranil ciclopentil tetrahidropiridopiridina, moduladores de actividad de receptores de citoquinas
KR930002325A (ko) 피리미딘 유도체
DE122005000058I1 (de) Depsipeptide, Herstellung und Anwendung
AR020016A2 (es) Compuestos derivados de la eritromicina, composiciones que los contienen, uso de los mismos para preparar un medicamento
DK526188A (da) Benzimidazolin-2-oxo-1-carboxylsyrederivater til anvendelse som 5-ht receptorantagonister i farmaceutiske praeparater
BR0015605A (pt) Composição e uso
AR029145A1 (es) Compuesto de hidroxamato pirrolidina sustituida, inhibidores de metaloproteasa, composicion farmaceutica que lo comprende y uso para elaborar una composicion farmaceutica
ES2172580T3 (es) 1,3-oxatiolanos sustituidos con propiedades antiviricas.
AR246267A1 (es) Composicion contra insectos de plantas que comprende derivados 23-oxo y 23-imino de compuestos ll-f28249 y metodos para preparar dichos derivados.
PE16399A1 (es) Compuestos heterociclicos de guanidinilo utiles como agonistas de alfa-2 adrenoreceptores
KR960010635A (ko) 약제학적 화합물
BRPI0017528B8 (pt) uso de uma composição contendo sal de cetotifeno
ES555992A0 (es) Procedimiento para la obtencion de e-isomeros de derivados y peptidos de n<-(2-ciano-2-alcoximino-acetil)-aminoacidos
PE29798A1 (es) Acetidinas
CO4970752A1 (es) Nuevos derivados de isatin y composiciones farmaceuticas conteniendo tales isatines
KR880004809A (ko) 안정화 제약 조성물
AR012730A1 (es) Compuestos derivados de aminocicloalquilpirrolidina sustituida cis-sustituidos, droga, agente antimicrobiano y compuesto intermediario
UA41880C2 (uk) Серотонінергічні похідні ерголіну і фармацевтична композиція
ATE194912T1 (de) Mittel zur vorsorge und heilung von typ i allergischen krankheiten
AR008695A1 (es) Composiciones farmaceuticas estabilizadas, basadas en la asociacion de quinupristina / dalfopristina; procedimiento para prepararlas, utilizacion dedichas composiciones y utilizacion del acido metansulfonico o del acido clorhidrico en la estabilizacion de dichas composiciones.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal